Timothy Yap, MD
Enriched profileRansom Horne, Jr. Endowed Professor for Cancer Research; Vice President and Head of Clinical Development, Therapeutics Discovery Division; Professor, Investigational Cancer Therapeutics (Phase I Program); Professor, Thoracic/Head and Neck Medical Oncology · The University of Texas MD Anderson Cancer Center
Timothy Yap is Ransom Horne, Jr. Endowed Professor for Cancer Research; Vice President and Head of Clinical Development, Therapeutics Discovery Division; Professor, Investigational Cancer Therapeutics (Phase I Program); Professor, Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 1,380 publications with 27,287 citations (h-index 77); ClinicalTrials.gov lists 31 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Timothy A. Yap, MD, is Ransom Horne, Jr. Endowed Professor for Cancer Research at The University of Texas MD Anderson Cancer Center. The public record shows 1,380 publications with 27,287 citations (h-index 77), centered on PARP inhibition in cancer therapy, interferon and immune responses, Cancer Genomics and Diagnostics. It also documents an investigator role on 31 registered clinical trials, industry payments reported by 25 companies, 1 NIH-funded awards (2021–2025).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: PARP inhibition in cancer therapy
- 31 registered trials on ClinicalTrials.gov
- Open Payments reporting from 25 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 74 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 233.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 31 registered studies on ClinicalTrials.gov. The most recent:
- PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
Sponsor: ProteinQure Inc.
Industry payments
Updated 14 Oct 2026
25 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202516 payments$20,284openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year20256 payments
- AstraZeneca UK LimitedProgram year20252 payments
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
52.6%Phenothiazine52.6%Prochlorperazine Maleate100%Part D≥17 patientsMetabolism & gastrointestinal
47.4%Serotonin-3 Receptor Antagonist47.4%Ondansetron Hcl100%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 2021–2025 per NIH RePORTER. The latest:
- Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors
University of Tx Md Anderson Can Ctr
FY2025$370,575R01CA255074 - Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors
University of Tx Md Anderson Can Ctr
FY2024$352,047R01CA255074 - Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors
University of Tx Md Anderson Can Ctr
FY2023$363,164R01CA255074
Congress activity
Updated 14 Oct 2026
221 congress contributions (2007–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 809: Food choices of patients with advanced cancer at start of early-phase combination trials with immune checkpoint blockade
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets.
Clinical cancer research
Article2026 - Novel Synthetic Lethal Therapeutic Strategies in Precision Oncology.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Review2026 - Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results.
Clinical cancer research
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01
- 02State-of-the-art strategies for targeting the DNA damage response in cancer1,199 citations2018
- 03Targeting the PI3K pathway in cancer: are we making headway?1,034 citations2018
- 04
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- X / Twitter
twitter.com/MoffittNews/status/1777409999893057610
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →twitter.com ↗ - LinkedIn
linkedin.com/posts/mdandersoncancercenter_aacr-yaptead-inhibitor-vt3989-is-well-tolerated-activity-7053813128710549504-N1SX
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - X / Twitter
x.com/ASCOPost/status/1982115313534558306
- X / Twitter
x.com/lungoncdoc/status/1892748601425559996
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- Chair
AACR Special Conferences Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗ - Member
AACR Clinical Trials Advisory Council
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗ - AACR Co-director
AACR/ASCO Methods in Clinical Cancer Research Workshop
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗ - Chair
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Secondary affiliations
appointments beyond the home institution- Associate Director of Translational Research
Khalifa Institute for Personalized Cancer Therapy, UT MD Anderson Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
Media & interviews
press, podcasts and appearances- Podcast interview
Audio Journal of Oncology (AudioMedica): "Selective PARP1 Inhibitor Saruparib Clinical Promise in Solid Tumors with Homologous Recombination Repair Deficiency," September 22
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →audiomedica.com ↗ - Recurring video interview contributor
VJOncology (Video Journal of Oncology) on early-phase clinical trials
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjoncology.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Hope Rugo, MD
City of Hope
Dennis Slamon, MD
University of California, Los Angeles